Miromatrix Medical Inc.

57 articles about Miromatrix Medical Inc.

• Miromatrix Reports Third Quarter 2023 Results

  11/14/2023

  Miromatrix Medical Inc. (Nasdaq: MIRO) (the “Company”), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results.

• Miromatrix to Present at the 2023 ISODP Organ Donation Congress

  10/11/2023

  Miromatrix Medical Inc. (NASDAQ: MIRO) today announced that it will be presenting at the 2023 International Society for Organ Donation and Procurement ("ISODP") Organ Donation Congress in Las Vegas, NV on October 18-21 at Mandalay Bay Resort.

• Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Mesa

  10/5/2023

  Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that CEO Jeff Ross will present at the 2023 Cell & Gene Meeting on the Mesa in Carlsbad, CA.

• Miromatrix Announces Participation in the ARM Tissue Engineering and Therapeutics Workshop

  9/5/2023

  Miromatrix Medical Inc. announced its participation in the upcoming Alliance for Regenerative Medicine Tissue Engineering and Therapeutics Workshop held on September 6, 2023.

• Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update

  8/14/2023

  Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update.

• Miromatrix to Report Second Quarter 2023 Financial Results

  7/25/2023

  Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will report financial results for the second quarter 2023 after market close on Monday, August 14, 2023.

• Miromatrix Poster Voted Best in Congress at the 2023 American Transplant Congress; Jack Lake Wins Lifetime Achievement Award

  7/13/2023

  Miromatrix Medical Inc. announced that its poster entitled Initial Preclinical Evaluation of a Bioengineered Kidney was selected Best in Congress at the recent American Transplant Congress.

• Miromatrix Announces CEO Jeff Ross, Ph.D. will Expand His Role by Resuming Leadership of R&D

  6/1/2023

  Miromatrix Medical Inc. announced that Miromatrix and John Barry have mutually agreed to end his employment as Vice President of Research and Development effective on or around June 13, 2023, and that Jeff Ross, Ph.D., Chief Executive Officer, will assume leadership responsibilities for the R&D organization.

• Miromatrix Presenting at the 2023 American Transplant Congress

  5/30/2023

  Miromatrix Medical Inc. announced it will be presenting at the upcoming 2023 American Transplant Congress held on June 3rd to June 7th, 2023 in San Diego, California.

• Miromatrix Announces Participation in the 20th Annual Craig-Hallum Institutional Investor Conference

  5/30/2023

  Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that members of the management team will participate in the upcoming 20th Annual Craig-Hallum Institutional Investor Conference on May 31st, 2023.

• Miromatrix Reports First Quarter 2023 Results and Provides Corporate Update

  5/11/2023

  Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported first quarter 2023 financial results and provided a corporate update.

• Miromatrix to Report First Quarter 2023 Financial Results

  4/27/2023

  Miromatrix Medical Inc. announced that the Company will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023.

• Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Med

  4/10/2023

  Miromatrix Medical Inc. announced that CEO Jeff Ross, Ph.D will present at the 2023 Cell & Gene Meeting on the Mediterranean.

• CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation

  4/5/2023

  CareDx, Inc. and Miromatrix Medical Inc. announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.

• Miromatrix Reports Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

  3/31/2023

  Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, reported fourth quarter and full year 2022 financial results and provided a corporate update.

• Miromatrix to Report Fourth Quarter and Full Year 2022 Financial Results

  3/15/2023

  Miromatrix Medical Inc. (NASDAQ: MIRO) today announced that the Company will report financial results for the fourth quarter and full year 2022 after market close on Friday, March 31, 2023.

• Miromatrix Medical Inc. Announces Proposed Public Offering of Common Stock

  3/7/2023

  Miromatrix Medical Inc. today announced that it has commenced an underwritten public offering of shares of its common stock.

• Miromatrix Medical Inc. Announces Pricing of $10 Million Public Offering of Common Stock

  3/7/2023

  Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $1.60 per share, before underwriting discounts and commissions.

• 

  Baxter and Miromatrix Join Forces to Develop Bioengineered Liver

  2/1/2023

  The partners will combine Miromatrix’s single-use bioengineered liver with Baxter’s PrisMax system, which is designed to provide individualized therapies to patients.

• Miromatrix Provides Update on miroliverELAP

  2/1/2023

  Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, provided a program update on miroliverELAP™.